Design Therapeutics, Inc.

Design Therapeutics appointed David Shapiro as Class III director, effective immediately, with a term ending at the 2027 annual meeting. Shapiro will receive annual cash retainers of $40K for board service and $5K for the Nominating Committee. He was granted options to purchase 60,000 shares and 7,500 shares.

Design Therapeutics, Inc. DSGN is headquartered in Carlsbad, CA.

Source